Last reviewed · How we verify
Nitrepin (NITRENDIPINE)
Nitrendipine works by blocking calcium channels in blood vessel walls, causing them to relax and widen.
Nitrendipine, also known as NITRENDIPINE, is a small molecule drug that targets the voltage-dependent L-type calcium channel subunit alpha-1C. It belongs to the drug class of nitrendipine and works by inhibiting the influx of calcium ions into smooth muscle cells, leading to vasodilation. Nitrendipine is used to treat hypertension, but its commercial status and approved indications are unknown. The drug has a half-life of 8.2 hours and bioavailability of 16%. Key safety considerations include its potential effects on blood pressure and calcium levels.
At a glance
| Generic name | NITRENDIPINE |
|---|---|
| Drug class | nitrendipine |
| Target | Voltage-dependent calcium channel gamma-1 subunit, ATP-binding cassette sub-family G member 2, Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | discontinued |
Mechanism of action
Imagine your blood vessels are like roads in your body. When they're narrow, it's harder for blood to flow. Nitrendipine helps to widen these roads by blocking the flow of calcium ions, which causes the muscles in the blood vessel walls to relax. This makes it easier for blood to flow and helps to lower blood pressure.
Approved indications
Common side effects
- Product prescribing error
- General physical health deterioration
- Renal cyst haemorrhage
- Intraductal papillary mucinous neoplasm
- Vena cava injury
- SARS-CoV-2 antibody test positive
- Rectal prolapse
- Carotid arteriosclerosis
- Dizziness
- Syncope
- Abdominal wall haemorrhage
- Delayed graft function
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Isolated Systolic Hypertension in the Elderly and Very Elderly (PHASE3)
- The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability. (PHASE4)
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- The Standardized Management of Hypertension in Rural Shaanxi (NA)
- Systolic Hypertension in Europe Placebo-Controlled Trial (PHASE2)
- Sympathetic Nerve Activity in Renal Failure (PHASE4)
- Treatment of Hypertension in Tibetan Adult Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |